AstraZeneca's lung cancer drug Imfinzi failed to improve disease-free survival in a late-stage trial.

AstraZeneca's cancer drug Imfinzi failed to improve disease-free survival in a late-stage trial for early-stage lung cancer patients. Imfinzi, a human monoclonal antibody, did not meet the primary endpoint of disease-free survival versus placebo in the ADJUVANT BR.31 Phase III trial. The drug is designed to block tumors' ability to evade the immune system while boosting the body's anti-cancer immune response.

June 25, 2024
8 Articles

Further Reading